Race Oncology (ASX:RAC) to trial Bisantrene on various cancers
- Race Oncology (RAC) has updated the market on its activities for the December 2019 quarter
- The company launched a 5-path clinical strategy for its cancer drug called Bisantrene
- Bisantrene is targeting cancers beyond Acute Myeloid Leukaemia (AML), such as ovarian and breast cancer
To trial Bisantrene on various cancers
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
-0.015(1.15%) |
Mkt cap ! $213.9M | |||
| Open | High | Low | Value | Volume |
| $1.33 | $1.35 | $1.28 | $34.20K | 26.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 682 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.35 | 1824 | 1 |
View Market Depth
| Last trade - 16.10pm 25/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.31 |
Change
-0.015 ( 0.38 %) |
||||
| Open | High | Low | Volume | ||
| $1.32 | $1.35 | $1.28 | 9710 | ||
| Last updated 15.59pm 25/04/2024 ? | |||||
| RAC (ASX) Chart |